Eupraxia Pharmaceuticals INC. (EPRX) — SEC Filings

Q: What are the key financial highlights for Eupraxia Pharmaceuticals INC.?

Key financial highlights for Eupraxia Pharmaceuticals INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: What is the investment thesis for EPRX?

The investment thesis for EPRX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings filed by Eupraxia Pharmaceuticals INC..

Q: Who are the key executives at Eupraxia Pharmaceuticals INC.?

Key executives at Eupraxia Pharmaceuticals INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Eupraxia Pharmaceuticals INC. stock?

Risk factors for Eupraxia Pharmaceuticals INC. (EPRX) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Eupraxia Pharmaceuticals INC.?

Forward-looking statements and predictions from Eupraxia Pharmaceuticals INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Eupraxia Pharmaceuticals INC.. Recent 6-K filing on Apr 22, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Eupraxia Pharmaceuticals INC. on SEC EDGAR

Overview

Eupraxia Pharmaceuticals INC. (EPRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 22, 2026: Eupraxia Pharmaceuticals Inc. filed a Form 6-K on April 22, 2026, reporting information as a foreign issuer. The filing includes a press release as Exhibit 99.1. The company's mailing and business address is located in Victoria, Canada.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 50 neutral. The dominant filing sentiment for Eupraxia Pharmaceuticals INC. is neutral.

Filing Type Overview

Eupraxia Pharmaceuticals INC. (EPRX) has filed 48 6-K, 1 SC 13G, 1 SC 13D with the SEC between May 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

Eupraxia Pharmaceuticals Files 6-K Report — 6-K · Apr 22, 2026 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on April 22, 2026, reporting information as a foreign issuer. The filing includes a press release as Exhibit 99.1
6-K Filing — 6-K · Nov 13, 2025
6-K Filing — 6-K · Nov 4, 2025
Eupraxia Pharmaceuticals Inc. Files September 2025 6-K Report — 6-K · Oct 1, 2025 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on October 1, 2025, for the month of September 2025. The company, incorporated in Canada with its principal execu
Eupraxia Pharmaceuticals Files 6-K Report — 6-K · Sep 29, 2025 Risk: medium
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on September 29, 2025, reporting a Material Change dated September 25, 2025. The company is based in Victoria, Br
Eupraxia Pharmaceuticals Files 6-K Report — 6-K · Sep 24, 2025 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on September 24, 2025, reporting as a foreign private issuer. The company is incorporated in Canada and its fisca
Eupraxia Pharmaceuticals Files 6-K with Underwriting Agreement — 6-K · Sep 23, 2025 Risk: medium
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on September 23, 2025, reporting on activities for the month of September 2025. The filing includes an Underwriti
Eupraxia Pharmaceuticals Files 6-K for September 2025 — 6-K · Sep 23, 2025 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on September 23, 2025, reporting for the month of September 2025. The company, headquartered in Victoria, British
Eupraxia Pharmaceuticals Files 6-K, Submits Form 40-F — 6-K · Sep 22, 2025 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on September 22, 2025, indicating it is submitting its annual report under cover of Form 40-F. The company, based
Eupraxia Pharmaceuticals Files 6-K with Material Change Report — 6-K · Sep 19, 2025 Risk: medium
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on September 19, 2025, reporting a Material Change Report dated February 20, 2025. The company, based in Victoria
Eupraxia Pharmaceuticals Files 6-K for September 2025 — 6-K · Sep 2, 2025 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on September 2, 2025, reporting for the month of September 2025. The company, incorporated in Canada and headquar
Eupraxia Pharmaceuticals Files 6-K with Financials — 6-K · Aug 13, 2025 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on August 13, 2025, reporting for the month of August 2025. The filing includes consolidated financial statements
Eupraxia Pharmaceuticals Files 6-K for 2025 Annual Report — 6-K · Jul 22, 2025 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on July 22, 2025, indicating it is submitting its annual report under cover of Form 40-F. The company, located in
Eupraxia Pharmaceuticals Files 6-K — 6-K · Jul 8, 2025 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on July 8, 2025, reporting as a foreign private issuer. The company is incorporated in Canada and its fiscal year
Eupraxia Pharmaceuticals Files 6-K, Submits Form 40-F — 6-K · Jun 3, 2025 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on June 3, 2025, for the month of June 2025. The company, headquartered in Victoria, British Columbia, Canada, is
Eupraxia Pharmaceuticals Files May 2025 Report — 6-K · Jun 2, 2025 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 30, 2025, reporting on activities for the month of May 2025. The filing includes a Management Information
Eupraxia Pharmaceuticals Files 6-K — 6-K · May 7, 2025 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 7, 2025, reporting as a foreign private issuer. The company is incorporated in Canada and its principal ex
Eupraxia Pharmaceuticals Files Q1 2025 Financial Report — 6-K · May 6, 2025 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 6, 2025, reporting its financial results for the three months ended March 31, 2025. The filing includes co
Eupraxia Pharmaceuticals Files 6-K for 2025 Annual Report — 6-K · May 5, 2025 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 5, 2025, indicating it is submitting its annual report under cover of Form 40-F. The company, located in V
Eupraxia Pharmaceuticals Files 6-K — 6-K · Apr 24, 2025 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on April 24, 2025, reporting as a foreign private issuer. The company is incorporated in Canada and its fiscal ye
Eupraxia Pharmaceuticals Files 6-K Report — 6-K · Mar 21, 2025 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on March 21, 2025, reporting on activities for the month of March 2025. The filing includes Exhibit 99.1, a press
Eupraxia Pharmaceuticals Files 6-K Report — 6-K · Feb 25, 2025 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on February 25, 2025, reporting information for the month of February 2025. The filing includes a press release d
Eupraxia Pharmaceuticals Files 6-K Report — 6-K · Feb 18, 2025 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on February 18, 2025, reporting for the month of February 2025. The filing includes Exhibit 99.1, a press release
Eupraxia Pharmaceuticals Files 6-K Report — 6-K · Nov 20, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on November 20, 2024, reporting on events for the month of November 2024. The filing includes Exhibit 99.1, which
Eupraxia Pharmaceuticals Files 6-K Report — 6-K · Nov 14, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on November 14, 2024, reporting for the month of November 2024. The filing includes a press release dated Novembe
SC 13G Filing — SC 13G · Nov 14, 2024
Eupraxia Pharmaceuticals Files 6-K Report — 6-K · Nov 13, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on November 13, 2024, reporting on events for the month of November 2024. The filing includes Exhibit 99.1, a pre
Eupraxia Pharmaceuticals Files 6-K with Financials — 6-K · Nov 7, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on November 7, 2024, incorporating by reference its consolidated financial statements for the three and nine mont
Freedman Files 13D on Eupraxia Pharmaceuticals — SC 13D · Nov 7, 2024 Risk: medium
Joseph S. Freedman filed a Schedule 13D on October 31, 2024, regarding his beneficial ownership of Eupraxia Pharmaceuticals Inc. common shares. The filing indic
Eupraxia Pharmaceuticals Files October 2024 6-K Report — 6-K · Nov 1, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on October 31, 2024, reporting for the month of October 2024. The filing includes Exhibit 99.1, a press release d
Eupraxia Pharmaceuticals Files 6-K Report — 6-K · Oct 28, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on October 28, 2024, reporting information for the month of October 2024. The filing includes Exhibit 99.1, which
Eupraxia Pharmaceuticals Files 6-K Report — 6-K · Oct 15, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on October 15, 2024, reporting information for the month of October 2024. The filing includes a press release dat
Eupraxia Pharmaceuticals Files 6-K Report — 6-K · Oct 10, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on October 10, 2024, reporting information for the month of October 2024. The filing includes Exhibit 99.1, which
Eupraxia Pharmaceuticals Files October 2024 6-K Report — 6-K · Oct 2, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on October 2, 2024, reporting on its activities for the month of October 2024. The filing includes a press releas
Eupraxia Pharmaceuticals Files 6-K, Includes Press Release — 6-K · Sep 19, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on September 19, 2024, reporting for the month of September 2024. The filing indicates that Eupraxia Pharmaceutic
Eupraxia Pharmaceuticals Files 6-K Report — 6-K · Sep 11, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on September 11, 2024, reporting information for the month of September 2024. The filing includes Exhibit 99.1, a
Eupraxia Pharmaceuticals Files 6-K, Includes Press Release — 6-K · Sep 4, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on September 4, 2024, reporting as a foreign private issuer. The filing indicates that the company will file annu
Eupraxia Pharmaceuticals Files 6-K with Financials — 6-K · Aug 7, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on August 7, 2024, incorporating by reference its consolidated financial statements for the three and six months
Eulexia Pharmaceuticals Files 6-K, Incorporates Press Release — 6-K · Aug 2, 2024 Risk: low
Eulexia Pharmaceuticals Inc. filed a Form 6-K on August 2, 2024, incorporating a press release dated August 2, 2024, as Exhibit 99.1. This filing is incorporate
Eupraxia Pharmaceuticals Files 6-K Report — 6-K · Jul 8, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on July 8, 2024, reporting for the month of July 2024. The filing includes Exhibit 99.1, a press release dated Ju
Eupraxia Pharmaceuticals Files July 2024 Report — 6-K · Jul 3, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on July 3, 2024, reporting on its activities for the month of July. The filing includes a press release dated Jul
Eupraxia Pharmaceuticals Files 6-K with Press Release — 6-K · Jun 6, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on June 6, 2024, reporting a press release dated June 6, 2024, and a report of voting. This filing incorporates E
Eupraxia Pharmaceuticals Files 6-K Report — 6-K · Jun 5, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on June 5, 2024, reporting information as of that date. The filing includes Exhibit 99.1, which is a press releas
Eupraxia Pharmaceuticals Files 6-K with Press Release — 6-K · May 23, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 23, 2024, reporting as a foreign private issuer. The filing includes a press release dated May 23, 2024, a
Eupraxia Pharmaceuticals Files 6-K Report — 6-K · May 22, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 22, 2024, reporting as a foreign private issuer. The filing includes Exhibit 99.1, a press release dated M
Eupraxia Pharmaceuticals Files 6-K Report — 6-K · May 21, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 21, 2024, reporting information as a foreign private issuer. The filing includes Exhibit 99.1, a press rel
Eupraxia Pharmaceuticals Files Notice of Shareholder Meeting — 6-K · May 15, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 15, 2024, to report its Notice of Annual General and Special Meeting of Shareholders. This filing is incor
Eupraxia Pharmaceuticals Files 6-K Report — 6-K · May 14, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 14, 2024, reporting for the month of May 2024. The filing includes Exhibit 99.1, a press release dated May
Eupraxia Pharmaceuticals Files 6-K with Financial Statements — 6-K · May 8, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 8, 2024, incorporating by reference its Consolidated Financial Statements. The company is incorporated in
Eupraxia Pharmaceuticals Files 6-K Report — 6-K · May 2, 2024 Risk: low
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 2, 2024, reporting information as of that date. The filing indicates the company is a foreign private issu

Risk Profile

Risk Assessment: Of EPRX's 47 recent filings, 0 were flagged as high-risk, 4 as medium-risk, and 43 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

Alex Rothwell
Alex Rothwe
Alex Roth
Bruce Cous
Joseph S. Freedman
Bruce Cousins
Bruce C

Top Tags

foreign-private-issuer (22) · press-release (21) · reporting (13) · regulatory-filing (12) · filing (10) · sec-filing (9) · annual-report (6) · pharmaceuticals (4) · 6-k (4) · 6-K (4)

Key Numbers

6-K Document Size: 5977 — Size of the main 6-K filing document in bytes.
Exhibit 99.1 Document Size: 6634 — Size of the press release exhibit in bytes.
SEC File Number: 001-41923 — Identifies the company's filing with the SEC
Financial Reporting Period: 9 months — Consolidated financial statements cover the nine months ended September 30, 2024.

Frequently Asked Questions

What are the latest SEC filings for Eupraxia Pharmaceuticals INC. (EPRX)?

Eupraxia Pharmaceuticals INC. has 50 recent SEC filings from May 2024 to Apr 2026, including 48 6-K, 1 SC 13G, 1 SC 13D. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of EPRX filings?

Across 50 filings, the sentiment breakdown is: 50 neutral. The dominant sentiment is neutral.

Where can I find Eupraxia Pharmaceuticals INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Eupraxia Pharmaceuticals INC. (EPRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Eupraxia Pharmaceuticals INC.?

Financial highlights for Eupraxia Pharmaceuticals INC. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.

What is the investment thesis for EPRX?

Investment thesis data for EPRX will be available once enriched filings are processed.

Who are the key executives at Eupraxia Pharmaceuticals INC.?

Key executives identified across Eupraxia Pharmaceuticals INC.'s filings include Alex Rothwell, Alex Rothwe, Alex Roth, Bruce Cous, Joseph S. Freedman and 2 others.

What are the main risk factors for Eupraxia Pharmaceuticals INC. stock?

Of EPRX's 47 assessed filings, 0 were flagged high-risk, 4 medium-risk, and 43 low-risk.

What are recent predictions and forward guidance from Eupraxia Pharmaceuticals INC.?

Forward guidance and predictions for Eupraxia Pharmaceuticals INC. are extracted from SEC filings as they are enriched.